Previous Close | 2.4200 |
Open | 2.6300 |
Bid | 2.7900 x 800 |
Ask | 2.9300 x 2200 |
Day's Range | 2.6300 - 2.9000 |
52 Week Range | 2.0000 - 16.3900 |
Volume | |
Avg. Volume | 50,675 |
Market Cap | 28.756M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.7630 |
Earnings Date | Nov 08, 2022 - Nov 14, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 22.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for TPST
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended June 30, 2022 and provided a corporate update. “In the second quarter, we presented promising trial results from TPST-1120, our novel PPARα antagonist, at the ASCO Annual Meeting. This was the first present
President Tom Dubensky, Ph.D., to Share Expertise on Next Generation Immuno-Oncolgy TargetsSOUTH SAN FRANCISCO, Calif., July 07, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class¹ therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Tom Dubensky, Ph.D., will participate in a panel titled “Developing Therapies for the Next Immuno-Oncology Targets” at the 2022 William Blair Biotech
TPST-1120 demonstrated monotherapy clinical benefit in patients with late-line advanced, poor-prognosis cancers where responses would be unexpectedRECIST responses observed with TPST-1120 combined with anti-PD1 therapy in patients who previously progressed on anti-PD1/PDL1 therapyPotential biomarker for patient responsiveness to TPST-1120 identified and will be further exploredTPST-1120 demonstrated the ability to reprogram the tumor microenvironment (TME) in a tumor type that is refractory to a